Posted by Michael Wonder on 17 Jun 2019
Eiger announces breakthrough therapy designation granted by FDA for avexitide for treatment of post-bariatric hypoglycemia
17 June 2019 - Third Eiger pipeline program granted breakthrough therapy designation.
Eiger BioPharmaceuticals today announced that the FDA has granted breakthrough therapy designation for avexitide for the treatment of post-bariatric hypoglycaemia.
Avexitide is a targeted, first-in-class, GLP-1 antagonist in development for the treatment of post-bariatric hypoglycaemia, a chronic, debilitating disorder for which there is no approved treatment.
